Clinical Trial: Dental Safety Profile of High-Dose Radioiodine Therapy

Study Status: Completed
Recruit Status: Completed
Study Type: Observational

Official Title: The Dental Safety Profile of High-Dose Radioiodine Therapy for Thyroid Cancer

Brief Summary: We aim to assess the incidence of oral and dental adverse events after high-dose radioiodine therapy for differentiated thyroid cancer.

Detailed Summary: Sialadenitis and xerostomia are the most frequent adverse events of high-dose radioiodine therapy. Saliva has vital functions in maintaining periodontal and oral health. Therefore, xerostomia not only impairs quality of life permanently, but may also increase the risk of caries and tooth extractions. Nevertheless, despite more than 6 decades of radioiodine therapy for thyroid cancer, large studies on long-term oral adverse events are still lacking. In the present study, we investigate the influence of high-dose radioiodine therapy on the long-term oral health.
Sponsor: University Hospital, Basel, Switzerland

Current Primary Outcome:

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: University Hospital, Basel, Switzerland

Dates:
Date Received: February 22, 2007
Date Started: September 2004
Date Completion:
Last Updated: November 13, 2007
Last Verified: October 2007